| This week's sponsor is Eli Lilly and Company. | |  | AHS 2018: Lilly Showcases Leadership in Migraine and Cluster Headache
For more than 50 years, Eli Lilly and Company has been committed to addressing the ongoing treatment challenges in neurology, primary headache disorders and chronic and recurrent pain. Learn more about Lilly's leadership in the development of innovative treatments for migraine and cluster headache here. |
Today's Rundown Featured Story | | | Tuesday, July 10, 2018 Acceleron and Celgene have the second phase 3 trial they wanted for beta thalassemia drug luspatercept, setting up filings in the U.S. and Europe for the first half of 2019. |
|
|
Top Stories Tuesday, July 10, 2018 The Wellcome Trust has created a £250 million ($331 million) nonprofit fund to bankroll high-risk, high-reward research. Wellcome sees the fund accelerating the progress of early-stage projects that may struggle to secure traditional grants or venture investments. Tuesday, July 10, 2018 Genetically engineered immunotherapy developer Tmunity Therapeutics has brought on Immunocore’s Christina Coughlin to be its chief medical officer and executive vice president, as the company gears up to move its T-cell therapies through early stage studies targeting solid and liquid tumors. Tuesday, July 10, 2018 Aquinox Pharmaceuticals will cut its workforce by 53% and shutter its site in San Bruno, California, in a bid to stay alive after it dumped its bladder pain drug, rosiptor. Tuesday, July 10, 2018 BioNTech and Genevant Sciences have entered into a broad, multipiece partnership. The agreement sets the companies up to work together on five programs targeting rare diseases and another five against cancers. Tuesday, July 10, 2018 Rochester, New York-based antibody developer Vaccinex hopes to raise $46 million in an IPO, listing on the Nasdaq under the symbol VCNX. The clinical-stage company focuses on monoclonal antibodies and antibody-drug conjugates targeting cancer, autoimmune disorders and neurodegenerative diseases. Monday, July 9, 2018 T-cell therapies have generated enthusiasm because of their high response rates in patients with lymphoma and leukemia, but the technology has proven difficult to translate to solid tumors. MIT researchers have developed nanoparticles with drug payloads that enhance the cells' tumor-killing power without causing off-target effects. | This week's sponsor is ExL Events. | | Can’t-miss interactive workshop at the industry's premier Safety Labeling & Packaging event!
This 3-day conference will provide attendees with the skills needed to understand how to develop & enhance an end-to-end process to ensure a compliant label for your drug packaging.
View the agenda and workshop details! Use Discount Code C1049FIERCE to save 15% |
Enrollment Showcase | | | Sponsored by: Bioinformatics at UTHealth SBMI UTHealth SBMI now offers a M.S. track in clinical and translational bioinformatics. |
|
|
Resources Sponsored by: Veeva See results from the Tufts eClinical Landscape Study – CRO Report on current data management practices, goals, and challenges for contract research organizations (CROs). Life Science Strategy Group Take this anonymous 10-minute survey to share your thoughts on leading eClinical technology solutions and earn up to $55 honoraria. Take the survey now! Sponsored by: Docusign Life science companies are experiencing a significant transformation in how they bring new products to market. |
|
